Post-transplant lymphoproliferative disorder (PTLD) is an aggressive complication of solid organ and hematopoietic stem cell transplantation that arises in up to 20% of transplant recipients. Infection or reactivation of the Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, in combination with chronic immunosuppression are considered as the main predisposing factors, however insight in ...

One well recognized and potentially serious complication of chronic immunosuppression in organ transplant recipients is post-transplantation lymphoproliferative disorders (PTLD). This accounts for 20% of all malignancies in transplant recipients, which is four times higher than the general population (1,2). The diagnosis of PTLD is often difficult, due to various manifestations resulting in lat...

Post-transplant lymphoproliferative disorders (PTLD) are a serious complication of transplantation with a high mortality. Most PTLD present within the first year of transplantation and are associated with Epstein-Barr virus (EBV) infection. Plasmablastic lymphoma (PBL) is a rare but aggressive disease originally described in patients with HIV, presenting most commonly in the jaw and oral mucosa...

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative disorders associated with immunosuppression and Epstein-Barr virus infection. PTLD is classified into three major categories: early lesions, polymorphic PTLD, and monomorphic PTLD. The majority of monomorphic PTLD cases are non-Hodgkin's lymphoma of B-cell origin. This retrospective study was c...

BACKGROUND The optimal reduction of immunosuppressive therapy (IST) in renal transplant patients with post-transplant lymphoproliferative disorders (PTLDs) is uncertain. As chemotherapy is immunosuppressive, IST may be stopped during this time without compromising graft function. Subsequent long-term reduction of IST reduces relapse risk, but may increase risk of graft rejection. METHODS We p...

Post-transplant lymphoproliferative disorder (PTLD) is the most common treatment related malignancy that occurs after solid organ transplantation (SOT). PTLD has extended from its initial description as an Epstein-Barr virus (EBV)-driven B-cell proliferation to include EBV-negative and non B-lineage cases. T-cell PTLD (T-PTLD) is rare in both adults and children. We report two cases of pediatri...

BACKGROUND Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of hematological diseases arising in context of immunosuppression after organ transplantation. PTLD can involve any organ; however, it is extremely rare in oral cavity. METHODS Using morphologic and immunophenotypic approaches we have studied a case of monomorphic PTLD of the tongue that developed in a patient follow...

AIM to analyze cases of BM PTLD in liver transplant recipients to find any specific predictor or prognostic factor associated with this disease localization. METHODS a comprehensive search of the existing literature was performed, and 173 liver recipients who had developed PTLD in their post transplant course from 19 studies were found and enrolled into analysis. 36 of the patients were BM PT...

Objectives: Post-Transplantation Lymphoproliferative Disorder (PTLD) is a wellrecognized complication of renal transplantation. The typical histopathological changes of PTLD could be a large increase in the number of B cell lymphocytes in lymphoid tissues, accompanied by multiple focal areas of necrosis. Plasma cell-rich acute rejection (PCAR) is a relatively new clinical entity and is characte...

Post-transplant lymphoproliferative disorders (PTLD) are lymphoid or plasmacytic proliferations that develop in immunosuppressed individuals, particularly in recipients of solid organs, bone marrow, or stem cell allograft. Although rare in the general population, the prevalence of PTLD is increasing among transplant patients, particularly as transplantations have become more frequent procedures...